Supreme Court Weighs Future Of Generic-Drug Defect Suits
Several U.S. Supreme Court justices questioned Tuesday whether the importance placed on a generic drug's warning label at trial suggests design defect claims against its manufacturer are preempted by federal law,...To view the full article, register now.
Already a subscriber? Click here to view full article